GSK, Merck KGaA Partner to Develop M7824.
GlaxoSmithKline and Merck KGaA inked a multibillion-dollar deal to develop a novel type of immunotherapeutic that simultaneously blocks the PD-L1 checkpoint protein and the TGFβ signaling pathway.